Homeostasis

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Retrieved on: 
Thursday, January 18, 2024
Granulocyte, Neutrophil, Chronic obstructive pulmonary disease, Inflammation, Standard of care, Homeostasis, Ligand, Cancer, Disease, S100, S100 protein, Vaccine

VSTM-1 is a cell-surface inhibitory receptor highly expressed on granulocytes, including neutrophils, and pulmonary monocytes that functions as a regulator of myeloid cell-driven inflammatory cascades.

Key Points: 
  • VSTM-1 is a cell-surface inhibitory receptor highly expressed on granulocytes, including neutrophils, and pulmonary monocytes that functions as a regulator of myeloid cell-driven inflammatory cascades.
  • Inhibitory signaling is induced when VSTM-1 binds to ligands such as cathelicidin and S100 proteins.
  • NextCure developed an agonist monoclonal antibody (mAb) against VSTM-1 to modulate hyperinflammatory conditions, restore homeostasis and prevent disease.
  • The data were presented in a poster presentation at the 2024 Keystone Symposium for Inhibitory Receptors in Immune Homeostasis, Disease and Therapy:

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1

Retrieved on: 
Tuesday, January 23, 2024
Biotechnology, FDA, Pharmaceutical, Health, Entrepreneurship, Obesity, DSM-IV codes, Erythropoietin, Therapy, Facial muscles, Muscular dystrophy, Walking, Orphan drug, Homeostasis, Growth hormone, Drug discovery, Insulin, Disorder, Food, Human, DM1, Protein, Myotonic Dystrophy Foundation, Myotonic dystrophy, Metabolism, Pharmaceutical industry

Juvena Therapeutics , a biotechnology company unlocking the potential of stem cell-secreted proteins to treat muscle and metabolic diseases including muscular dystrophies and obesity, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the company’s flagship candidate, JUV-161.

Key Points: 
  • Juvena Therapeutics , a biotechnology company unlocking the potential of stem cell-secreted proteins to treat muscle and metabolic diseases including muscular dystrophies and obesity, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the company’s flagship candidate, JUV-161.
  • JUV-161 is an investigational therapeutic for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare, multi-systemic, autosomal dominant inherited disease and the most common form of adult muscular dystrophy.
  • “People living with DM1 deserve safe, effective, and rejuvenating treatments that can repair and restore tissue health to improve muscle function and metabolism,” said Dr. Hanadie Yousef, Co-Founder and CEO of Juvena Therapeutics.
  • Additionally, Juvena has identified multiple secreted protein hits that induce disease-modifying effects across several metabolic organs and therapeutic areas.

Fauna Bio Researcher Awarded NASA Early-Stage Grant to Study Hibernation in Space

Retrieved on: 
Monday, January 22, 2024
Data Management, Biotechnology, Aerospace, Technology, Manufacturing, Health, General Health, Pharmaceutical, Research, Science, Hardware, Hope, International Space Station, NIAC, BioServe Space Technologies, Radiation, University of Colorado, Homeostasis, University, Hibernation, Disease, Human body, Phenotype, Immobilization

Fauna Bio is partnering in the project with BioServe Space Technologies at the University of Colorado – Boulder.

Key Points: 
  • Fauna Bio is partnering in the project with BioServe Space Technologies at the University of Colorado – Boulder.
  • "We’re thrilled to partner with Fauna on this project to evaluate animal hibernation in space,” said Tobias Niederwieser, Ph.D., Assistant Research Professor, BioServe Space Technologies, University of Colorado – Boulder.
  • "This NIAC grant provides initial funding to study the potential of animal hibernation in space, to expand our knowledge of human disease development and prevention," said Ashley Zehnder, Ph.D., CEO & Co-Founder, Fauna Bio.
  • “We aim to unlock the secrets of hibernation in space, with the hope of revolutionizing space medicine and developing novel therapies for human health."

Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation

Retrieved on: 
Monday, January 8, 2024
Human, Treatment, Chronic pain, Homeostasis, PLXDC2, Ulcer, Disease, UC, Doctor of Philosophy, ECCO, Pharmacokinetics, NLRX1, Abstract, UZ Leuven, Library, Congress, European, Effect, Inflammatory Bowel Diseases, Inflammation, Patient, Translation, Immunometabolism, Safety, Landos, NEXUS, Pharmaceutical industry

The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.

Key Points: 
  • The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.
  • The ECCO congress will take place February 21-24, 2024 in Stockholm, Sweden.
  • We are excited to present data from multiple studies including the impact of NX-13 on eosinophil infiltration and visceral hypersensitivity, as well as confirming its relevancy in multiple models and species.
  • Additionally, we are pleased to share new preclinical insights into the potential role of PLXDC2 in ulcerative colitis,“ said Fabio Cataldi, M.D., Executive Vice-President & Chief Medical Officer at Landos.

TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration

Retrieved on: 
Wednesday, January 3, 2024
Biotechnology, Pharmaceutical, Health, Inflammation, Workflow, Patient, Therapy, Homeostasis, Tissue, Collaboration, Exercise, Pharmaceutical industry

TRexBio announced the research collaboration focusing on the discovery of novel targets for immunology and inflammation in January 2022.

Key Points: 
  • TRexBio announced the research collaboration focusing on the discovery of novel targets for immunology and inflammation in January 2022.
  • In connection with the exercise of this option, TRexBio has earned a milestone payment and may be entitled to additional milestone and royalty payments as the program advances.
  • “We are delighted that our collaboration has delivered several promising targets and that Johnson & Johnson Innovative Medicine has exercised its first option for one,” said Laura Berner, Chief Operating Officer of TRexBio.
  • The company’s lead program, TRB-061, is an agonist designed to preferentially augment tissue Treg for the treatment of inflammatory diseases.

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

Retrieved on: 
Tuesday, December 19, 2023
Marketing, Metabolism, Homeostasis, FDA, Vaccine, Retinitis pigmentosa, Regenerative medicine, Trial of the century, RP, Doctor of Philosophy, Mutation, RHO, LCA, Reproduction, Patient, Safety, Paratriathlon, Leber congenital amaurosis, Pharmaceutical industry

“FDA’s decision also reinforces the sense of urgency to bring a therapeutic option to these patients.”

Key Points: 
  • “FDA’s decision also reinforces the sense of urgency to bring a therapeutic option to these patients.”
    RMAT designation is part of the 21st Century Cures Act.
  • The program was created to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure a serious condition.
  • Receiving RMAT designation offers sponsor companies all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with the FDA.
  • RHO mutations affect more than 10,000 of the 110,000 people in the United States diagnosed with RP.

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Retrieved on: 
Wednesday, December 13, 2023
University of Arizona, Connective tissue, Geographic atrophy, System, Homeostasis, Paratriathlon, Lipid metabolism, College of Medicine, Vaccine, AMD, Hope, MD, Doctor of Philosophy, Eye, Clinical trial, Inflammation, Medicine, University, Vance DeGeneres, Armada, Oxidative stress, ARC, Safety, Retina, Life, Pharmaceutical industry

“We are very pleased to continue advancing our ophthalmic gene therapy pipeline, which remains the Company’s primary focus.”

Key Points: 
  • “We are very pleased to continue advancing our ophthalmic gene therapy pipeline, which remains the Company’s primary focus.”
    This Phase 1/2 trial will assess the safety and efficacy of OCU410 for geographic atrophy (GA) secondary to dAMD and will be conducted in two phases.
  • Phase 2 is a randomized expansion phase in which subjects will be randomized in a 1:1:1 ratio to either one of two OCU410 dose groups or to an untreated control group.
  • OCU410 is a potential curative therapy with a single sub-retinal injection that targets multiple pathways causing dAMD, including lipid metabolism, inflammation, oxidative stress, and complement activation.
  • Currently, the other therapeutic options available target only complement activation and require approximately 6-12 intravitreal injections annually.

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Monday, December 11, 2023
Patient, Quality of life, Erythropoietin, Protein, Exposition, Fever, Reticulocyte, Homeostasis, Bone marrow, MF, IWG, Haematopoiesis, Research, Erythropoiesis, Diarrhea, Anemia, KROS, Fatigue, Nausea, Headache, RBC, Iron overload, Society, MDS, Therapy, Weakness, Ruxolitinib, Thrombocytopenia, ASH, TI, Week, Periodic breathing, MBBS, Biomarker, Safety, Acute myeloid leukemia, HTB, Cytopenia, Disorder, Pharmaceutical industry

“Additionally, we are encouraged by the preliminary data from the lowest three dose cohorts from our ongoing Phase 2 clinical trial in MF.

Key Points: 
  • “Additionally, we are encouraged by the preliminary data from the lowest three dose cohorts from our ongoing Phase 2 clinical trial in MF.
  • Data for hematological response and markers of hematopoiesis were presented from exploratory analyses of these mITT24 patients.
  • All data presented from this trial is as of the data cut-off date.
  • 13 of those 18 patients (72.2%) achieved TI for at least 24 weeks over the first 48 weeks of treatment.

OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration

Retrieved on: 
Wednesday, November 29, 2023
Seniors, Biotechnology, Pharmaceutical, Optical, Health, Genetics, Consumer, Clinical Trials, Intravitreal injection, Safety, Neovascularization, Visual acuity, RNA interference, Homeostasis, Vance DeGeneres, Patient, Small RNA, DLT, Therapy, RNA, Harvard Medical School, AMD, Macular degeneration, Sirna Therapeutics, KOSDAQ, Quality of life, Paratriathlon, Inflammation, Optimism, Pharmaceutical industry

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive results from a Phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).

Key Points: 
  • OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive results from a Phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).
  • This phase 1 study is a multi-center, single-dose, dose-escalating study to evaluate the safety and tolerability of OLX10212 in patients with neovascular AMD.
  • The primary endpoints of this study were safety and tolerability assessments associated with each intravitreal OLX10212 injection.
  • The safety and tolerability evaluations, together with preliminary BCVA improvement of OLX10212 encourage further development of OLX10212 for AMD.

COVID-19’s impact on the vagus nerve, inflammatory reflex & long COVID: Feinstein Institutes & Karolinska Institutet study outlines potential therapies

Retrieved on: 
Wednesday, November 29, 2023
Health, Medical Devices, Infectious Diseases, COVID-19, Research, Science, Biotechnology, Karolinska Institute, DRS, Cytokine, Biomedical engineering, Interface (computing), Brain, Journal of Internal Medicine, Inflammatory Bowel Diseases, Disease, Homeostasis, Patient, Multimedia, Journal, Pelvic floor dysfunction, Pulmonary hypertension, Rheumatoid arthritis, Nervous system, Heart rate, Arthritis, Internal medicine, JIM, Neuroscience, Medical research, Molecular medicine, Paralysis, Periodic breathing, Credit, Cancer, Acetylcholine, Famotidine, VNS, Doctor of Philosophy, Sensation, SARS-CoV-2, Diabetes, Outline, Inflammation, Vagus nerve, HMGB1, Pharmaceutical industry, MD

View the full release here: https://www.businesswire.com/news/home/20231129335345/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231129335345/en/
    Dr. Kevin J. Tracey co-authored a new paper on the relationship between SARS-CoV-2 and the vagus nerve.
  • They also discussed potential therapies, particularly to reduce the progression of COVID-19 in infected patients as well as long COVID-19 treatment options.
  • “Studying the connection between COVID-19 and the vagus nerve is an important research avenue that needs further study,” said Dr. Andersson.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.